The Trendlines Group Ltd.
TRNGF
Other OTC0.03
USD
- -
- -
The Trendlines Group Ltd.
TRNGF
(Other OTC)
Recent
price
0.03
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- The Trendlines Group Ltd. The Trendlines Group Ltd. (SGX: 42T; OTCQX: TRNLY) is an Israel-based life sciences innovation commercialization company that invents, discovers, invests in, partners with, and incubates innovation-based medical technologies and agricultural technologies to improve the human condition. Founded in 1993 and headquartered in Misgav, Israel, with additional offices in Tel Aviv, Israel; Singapore; and Beijing, China, the company operates principally through four business units, including Israeli government-franchised incubators Trendlines Medical and Trendlines Agtech, Singapore-based Trendlines Medical Singapore, and in-house Trendlines Labs; it maintains a portfolio of more than 50 companies across medtech sectors such as cardiology, neurology, esthetics, gastroenterology, spine and orthopedics, surgery, urology and women's health, and agrifood sectors encompassing aquaculture and animal health, crop protection, digitization and robotics, future food and ingredients, and net-zero technologies. Core offerings encompass seed, start-up, early venture, and late-stage investments in areas including medical devices, biotechnology, pharmaceuticals, cleantech, and security technologies; comprehensive incubation services such as business development, partner and channel development, market strategies, R&D, commercialization, finance and funding strategies, administrative support, and marketing communications; and active involvement from technology validation through business building and exits via mergers, acquisitions, or public listings, leveraging its own capital alongside government funding primarily in Israel and Singapore with a focus on international exposure through partnerships with investors, strategic players, inventors, and governments. The company targets entrepreneurs and portfolio firms serving global markets in healthcare and agrifood chains, emphasizing sustainable solutions like AI-driven crop disease analytics platforms, cell-cultured cocoa ingredients, minimally invasive pelvic organ prolapse repair devices, phage-based crop protection, bioactive coral-based bone grafts, and precision biopsy tools. Recent developments include portfolio company milestones such as IBI Ag completing a $10 million Series A funding round led by Corteva in November 2025, with participation from The Trendlines Group; Celleste Bio achieving production of chocolate-grade cocoa butter using cell-cultured technology and closing a $4.5 million seed round led by Supply Change Capital with Mondelēz International’s SnackFutures Ventures; Arcuro Medical securing Series A financing led by Varana Capital and attaining FDA 510(k) clearance for its SuperBall RC rotator cuff device; EcoPhage entering a distribution agreement with Maian for Brazil; Phytolon nearly tripling manufacturing efficiency for natural food colors in partnership with Ginkgo Bioworks; the cessation of Chief Financial Officer Igor Vatenmacher effective November 13, 2025; and a January 2025 loan facility of US$2.3 million from Agriline to support portfolio investments.